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Abstract
The clinical case illustrates the daily practice with an individualized, 
adjusted thromboprophylactic dose of apixaban (2.5 mg twice-daily, 
follow-up for 20 months), mandatory indicated as a continuous the-
rapy for secondary prevention of systemic arterial embolism and re-
current venous thromboembolic events, in an elderly obese patient, 
associating multiple pathological conditions (chronically anticoagula-
ted for non valvular atrial fibrillation and stroke sequelae, multiple me-
tabolic comorbidities such as type 2 diabetes mellitus, moderate renal 
insufficiency, hyperuricemia), who submitted a severe “unprovoked” 
phlegmasia alba dolens in the sound (left) lower limb, a decade after 
a (most possible) iatrogenic deep vein thrombosis at the paralyzed 
(right) limb. 
Thromboprophylaxis for an extended time, without any medical 
complications (neither systemic or venous thrombotic events, nor he-
morrhagic ones) confirmed the product`s efficacy and safety profile. 
Physiopathological considerations and essential pharmacological con-
siderations were discussed, focused on the individualized safe thera-
peutic approach. 
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Introduction 
Contemporary registers for randomized evaluation of long-term anti-
coagulant therapy indicated for thromboprophylaxis in chronic atrial fi-
brillation (GARFIELD 60,000 patients in 34 countries, RE-LY AF 15,400 
patients in 46 countries) revealed that in North America only 65.7% of 
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patients with atrial fibrillation (AF) at risk for throm-
boembolic events are treated with oral anticoagu-
lants [1].
Efficient secondary cardioembolic stroke pro-
phylaxis with oral anticoagulants has a large medical 
and socioeconomic variation, between developed 
and poor countries. The mean time in the thera-
peutic range (TTR) in Western Europe was found 
to be 62.4%, high in North America 50.9%, but 
tiny in India, China, Southeast Asia and Africa (TTR 
between 32%- 40%) [1].
Amid an imperfect anticoagulation may occur sys-
temic or venous thrombotic events, with or without 
evident trigger or risk factors. 
Deep vein thrombosis (DVT) and pulmonary em-
bolism (PE), collectively denominated venous throm-
boembolism (VTE), represent a common, severe cli-
nical condition, associated to significant morbidity 
and mortality, but preventable. Despite adequate 
curative and prophylactic treatment, many patients 
(approximately 10%- 30%) with symptomatic DVT 
and/or PE will experience a recurrent thrombotic 
event within subsequent years [2]. 
Case Presentation
A 65 years-old man, non-smoker, with a past me-
dical history significant for metabolic syndrome 
(obesity IMC= 31.8; 92 kg, 170 cm, type 2 diabetes 
equilibrated with diet, dyslipidemia and hyperten-
sion) was diagnosed in 2004 (at 55 years-old) with 
non valvular atrial fibrillation (NVAF) complicated 
with cardio-embolic stroke in the left middle cere-
bral artery territory. 
In 2004 was admitted in our Rehabilitation Cli-
nic, in post-acute stage after stroke, with a flac-
cid right hemiplegia, global aphasia, and an acute 
proximal deep vein thrombosis (DVT) at the right 
lower limb, (most probably) iatrogenic post inco-
rrectly administration of infusions in the superficial 
veins of the ankle. The acute venous episode was 
adequately treated with a low-molecular-weight 
heparin (LMWH). He was discharged on medica-
tion for blood pressure control and antiarithmics, 
neurotrophics, statin, and anticoagulation with a 
vitamin K antagonist (VKA, acenocumarol/sintrom), 
successfully administered for both prophylactic tar-
gets: secondary prevention of cardio-embolic stroke 
or non-(central nervous system) CNS embolism, and 
DVT recurrence. 
He lived in the family, dependent for most of 
the basic ADL items, with disabling sequelae: right 
spastic hemiparesis (with typical arterial topogra-
phy) and mixed aphasia (mainly expressive). He was 
able to walk for short distances, assisted by his wife, 
and had no residual postphlebitis syndrome. 
During the entire decade 2004-2014 he was 
chronically anticoagulated with the above-mentio-
ned VKA. He did not receive any factor incriminated 
in possible INR modification (occasionally antibiotic 
therapy, but neither amiodarone, herbal, aspirin, nor 
alcohol consumption). The retrospective estimation 
of how long the patient was efficiently anticoagula-
ted (therapeutic time in range, TTR%) is depicted in 
Figure 1. From a total number of 43 tests, 33 were 
within range (TTR 76.7%) 
In time, the patient gradually developed a mo-
derate chronic kidney disease (CKD); in only a 
few occasions the creatinine clearance (CrCl) had 
a tiny decrease under the upper edge of 30 ml/
min/1.73m2 (considered borderline for a severe 
Figure 1:  Retrospective evaluation of VKA (aceno-
cumarol) anticoagulation efficacy (INR 
in black, TTR in grey).
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CKD). The retrospective evolution of the blood 
creatinine values and creatinine clearance is repre-
sented in Figure 2. 
The “strange” graphic aspect of CrCl is due to 
the fact that the patient addressed 4 different priva-
te laboratories during 2008-2010, 2011, 2012-2013, 
2014-2016; this “perplexed” element was not noti-
ced during isolated consultations.
Hyperuricemia (occurred since 2013, treated with 
allopurinol 100 mg QD), completed the clinical pic-
ture of the metabolic syndrome.
In September 2014 the patient experienced a res-
piratory viral infection, occurred amid an episodic 
inefficient anticoagulation treatment with acenocu-
marol (INR 1.9); in a few days he developed an acute 
superficial-vein phlebitis of the healthy (left) shank, 
misdiagnosed and neglected (treated at home with 
topic NSAIDs and heparin ointments).
Evolution was rapidly progressive to an extensi-
ve ascendant proximal left DVT (Figure 3). He was 
admitted in our Rehabilitation Clinic presenting the 
classical signs of phlegmasia alba dolens, with pain 
at rest and mobilization (in standing and walking), 
and an “aggressive” trend for bilaterally extension 
to the common femoral and iliac veins (referred as 
iliofemoral DVT). Local examination revealed an ob-
vious trajectory of the safena magna vein (visible, 
palpable and tender).
Significant laboratory coagulation tests (at admis-
sion, in 2014) revealed a therapeutically ineffective 
prothrombin time (PT/ INR 15.5s/1.9) and elevated 
fibrinogen 765 mg/dl. Post therapeutically values of 
fibrinogen decreased at 648 mg/dL, respectively at 
345 mg/dL.
D-dimer assay had also a favourable outcome 
(from 1 mcg/mL at admission, decreased to 0.7 
mcg/mL post therapeutically, and normalised at 
discharge to 0.5 mcg/mL), in parallel with seriated 
ultrasound (venous duplex Doppler) examinations, 
who confirmed the recanalization of the deep ve-
ins. 
MR Angiography of the iliofemoral veins was not 
available (from objective technical reasons).
Figure 3:  Left DVT phlegmasia alba dolens (2014) 
with good subsequent outcomes. The 
contrasting clinical difference between 
the thickness of the lower limbs is due 
to the amyotrophic aspect of the right 
lower limb and the residual post phle-
bitis syndrome on the left (2015, 2016). 
[Written informed consent was obtai-
ned from the patient for publication, as 
well as our hospital’s Bioethics Commis-
sion approval].
Figure 2:  Retrospective evaluation of the chronic 
kidney disease (blood creatinine and 
creatinine clearance)
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Routine X-ray of the chest pointed out left ven-
tricle hypertrophy. Cerebral CT confirmed the is-
chemic stroke sequelae. ECG detected ST-T wave 
abnormalities (ischemic heart disease) and AF. 
Based on the clinical picture, history and ab-
sence of evident thrombotic risk factors, the left 
iliofemoral DVT episode was considered as an 
“idiopathic”/“unprovoked” thrombotic event.
Discussion 
The clinical case has some particularities to consider:
Occurrence of two DVT severe episodes, at each 
separate limbs, temporo-spatially distributed at 10 
years interval, the first (most probably) iatrogenic, 
the last (apparently) “unprovoked”, with a rapidly 
progressive ascendant evolution, localized at the 
non-paralyzed lower limb, in a patient previously 
(but non constantly efficient) anticoagulated with 
VKA 
Uncommon presentation (at admission) as an 
acute massive venous thrombosis, phlegmasia alba 
dolens
The etiologic diagnosis has two major “weak 
points“: one is represented by the missing infor-
mation concerning a “not so uncommon cause, of 
a common condition”, the May-Thurner syndrome, 
also called iliocaval compression syndrome [3] (resul-
ting from the arterial conflict upon the left common 
iliac vein, inflicted by the pulsatile compression of 
the left internal iliac artery), that should be consi-
dered in patients with proximal DVT, in absence 
of identifiable triggers. An invasive venography was 
not performed and considered unnecessary (due to 
safety reasons, lack of the technical device in the 
hospital, and the subsequent good clinical evolu-
tion). 
The other limitation consists in absence of pre-
vious information regarding a possible hypercoagu-
lable disorder, responsible for most cases of spon-
taneous DVT. Status of hereditary or acquired hy-
percoagulability was not investigated, because its 
specific biological markers (antithrombin, protein C, 
or protein S deficiencies) were already altered by 
previous administration of VKA 
The respiratory viral infection (recently preceding 
the thrombotic episode) was incriminated as a pos-
sible trigger factor for the iliofemoral DVT in this 
particular case, probably liked to a transiently ele-
vated level of antiphospholipid antibodies, usually 
induced by inflammation or infections. In an epide-
miological study, Clayton et al, emphasized a strong 
association between recent respiratory infections 
and VTE, noticed an increased risk for DVT in the 
month following infection and for PE in 3 months 
following infection, both persisting up to a year [4]. 
Hyperuricemia, considered an independent risk 
factor for cardiovascular disease in middle-aged and 
elderly, was out of discussion, due to the fact that 
urate-lowering therapy (allopurinol) co-administered 
with acenocoumarol may increase the anticoagulant 
effect of the VKA.
Clinical prediction rules, biological parameters 
and ultrasound imagery were used to tailor the-
rapy to the DVT severity. Anticoagulation options 
for the acute DVT episode included unfractionated 
heparin, low molecular weight heparin, fondapa-
rinux and the direct oral anticoagulants (DOACs). 
It was preferred LMWH (Nadroparine/ Fraxiparine 
7,600 anti-factor Xa, subcutaneously, twice-daily – 
SQ BID), due to its advantages over unfractionated 
heparin (predictability, dose-dependent plasma le-
vels, a long half-life permitting once-/or twice-daily 
administration, without laboratory monitoring, less 
bleeding risk). The severity of the case imposed a 
double dose of LMWH than the usually recommen-
ded (85 anti-factor Xa IU/Kg) for 20 days, followed 
by apixaban 2.5 mg BID. 
Favourable outcomes were reflected by the clini-
cal evolution of the lower limbs diameters: left thigh 
= 65 cm (admission)/55.5 (discharge); left shank = 
46 cm (admission)/41.5 (discharge); the right (paraly-
zed) thigh = 55 cm (admission)/52 (discharge), right 
shank = 39 cm (admission)/37.5 (discharge). 
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Improvement of the biomarkers (D-dimer pro-
gressive normalization from 1 mcg/mL at admission 
to 0.7 and 0.5 mcg/mL), in conjunction with ultra-
sound serial examinations (confirming the natural 
remodeling process of the thrombus and the ve-
nous recanalization), were the paraclinical decision 
milestones, indicating the moment to reconsider the 
anticoagulant for a “long cruise” therapy and the 
shift to DOAC (apixaban). The FDA recommended 
dosage to prevent recurrence (2.5 mg PO BID) was 
fit to the patient`s moderate renal impairment. The 
good clinical outcomes and the quite stable para-
meters of the serum creatinine, permitted a safely, 
extended anticoagulation with apixaban, during the 
last 20 months (Oct 2014-May 2016). 
Extended duration of anticoagulation (20 months 
forwards) targeted both reduction of the risk for 
stroke and systemic embolism due to NVAF, and 
prophylaxis of a possible recurrent VTE.
CHEST antithrombotic therapy guidelines for ve-
nous thromboembolism (VTE) recommends [5]: 
In patients with DVT of the leg or PE and no can-
cer, a long-term (3 months) anticoagulant therapy 
with dabigatran, rivaroxaban, apixaban or edoxa-
ban, over vitamin K antagonist (VKA) therapy (Gra-
de 2B)
In patients with DVT of the leg or PE who receive 
extended therapy, no need to change the choice of 
anticoagulant after the first 3 months (Grade 2C)
Phase III studies indicated that dabigatran, ri-
varoxaban, apixaban or edoxaban [“novel” 
NOACs/“direct” DOACs/“target-specific” TSOAs 
– all the names, being “La même Jeannette, mais 
autrement coiffée”] are a more convenient alterna-
tive with practical advantages, as effective as the 
conventional therapy with LMWH and vitamin K 
antagonists (warfarin, acenocumarol) for the acute 
VTE [6-10] and for extended prophylaxis. 
This class of new discovered oral anticoagulants 
brings consistent efficacy (reduced recurrent VTE or 
VTE-related death compared to placebo) [11], rela-
tive safety (significantly reducing the risks of major 
bleeding) [6, 12] and convenience, compared with 
antivitamin K (acenocumrol or warfarin) [13].
From all the selective oral factor Xa inhibitors, 
apixaban seems to be associated with the lowest 
risk for bleeding than the other DOAC’s in exten-
ded treatment of venous thromboembolism [10] 
and efficiency in both therapeutic and prophylactic 
doses [14]. 
Currently, apixaban is approved for secondary 
prophylaxis of stroke and systemic embolism in pa-
tients with NVAF, for the treatment of acute clinical 
form of DVT/PE (VTE), respectively risk reduction of 
recurrent VTE following the initial therapy. These 
last pharmacological targets were extended by FDA 
in autumn 2014, so the affiliated term “novel” ap-
pears … quite obsolete.
Due to its favorable pharmacokinetic properties 
(simple BID administration in fixed doses, low inter- 
and/or intra-subject variability, multiple elimination 
pathways, not exclusively limited on either renal or 
hepatic metabolic mechanisms, not requiring labo-
ratory monitoring) all important aspects in boosting 
compliance [15, 16] both the patient and his wife 
had a good psychological adherence and discipline 
to therapy.
The patient had a moderate risk for major blee-
dings (rated 2 on the HAS-BLED scale) [17]. From 
a comprehensive list of 14 predisposing factors for 
bleeding (increasing age, previous bleeding, cancer, 
renal or liver failure, previous stroke, diabetes, ane-
mia, thrombocytopenia, antiplatelet therapy, poor 
anticoagulant control, recent surgery, alcohol abuse, 
frequent falls), only the previous stroke and T2DM 
could be noticed [18]. The new ABC (age, biomar-
kers, clinical history) biomarker-based risk score for 
major bleeding was not available for follow-up, 
although it seems to have a better discrimination 
and utility than the HAS-BLED score [19]. 
The clinical case underlies the importance of an 
individualized therapeutic approach (after careful as-
sessment of benefits against risks) and confirms the 
product`s efficacy and safety profile, described in 
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seven Phase III trials, cumulating more than 21,000 
patients (4,000 patients in treatment studies, more 
than 5,000 subjects in prophylaxis studies, with an 
average total exposure up to 221 days, and respec-
tively more than 11,000 cases with NVAF, treated 
with apixaban up to 1.7 years) [20]. Careful follow-
up and individualized dose of apixaban reduced 
simultaneously the risk for both stroke and non-
CNS embolism, respectively the risk for intracranial 
hemorrhage and/or fatal bleeding.
Conclusions
The clinical case illustrated the daily practice with an 
individualized, adjusted thromboprophylactic dose 
of apixaban (2.5 mg BID), mandatory indicated as 
a continuous therapy for prevention of systemic ar-
terial embolism and recurrent venous thromboem-
bolic events, in an elderly obese patient, associating 
multiple chronic conditions (NVAF, stroke sequelae, 
multiple metabolic comorbidities such as T2DM, hy-
peruricemia, moderate renal insufficiency), and con-
firmed the product`s efficacy and safety profile in 
extended time therapeutically approach (followed-
up for 20 months).
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